{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T06:52:25Z","timestamp":1697611945006},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,6,20]],"date-time":"2002-06-20T00:00:00Z","timestamp":1024531200000},"content-version":"vor","delay-in-days":139,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["APMIS"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:p>Lymphoproliferative disease induced by EBV (EBV\u2010LPD) is a complication of allogeneic transplantation caused by T\u2010cell immunodeficiency. EBV\u2010LPD responds poorly to conventional treatment modalities. Recently, adoptive transfer of EBV\u2010specific, HLA\u2010class I\u2010restricted CTL lines was shown to be effective both as prophylaxis and as treatment of EBV\u2010LPD. The CTL lines are produced by in vitro selection of EBV\u2010specific memory T cells contained in MNC of EBV\u2010seropositive individuals by repeated stimulation with irradiated EBV\u2010transformed cells. The non\u2010EBV\u2010reactive and potentially alloreactive cells remain unactivated. Twenty\u2010one CTL lines were initiated. All were successfully generated and shown to be HLA\u2010restricted and EBV\u2010specific as well as CD8\/CD4 and CD45RO positive T cells. The majority of the CTL lines were generated from BMT donors, but two CTL lines were obtained from solid organ transplant recipients receiving immunosuppression. Evidence of probable in vivo efficacy is presented. Development of efficient adoptive T\u2010cell strategies for EBV\u2010positive malignancies could serve as a model for treatment of other viral or malignant disorders.<\/jats:p>","DOI":"10.1034\/j.1600-0463.2002.100205.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:25:31Z","timestamp":1047353131000},"page":"148-157","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Generation of EBV\u2010specific CTLs suitable for adoptive immunotherapy of EBV\u2010associated lymphoproliferative disease following allogeneic transplantation"],"prefix":"10.1111","volume":"110","author":[{"given":"Thomas","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Vindel\u00f8v","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,6,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.2.520.520"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.59.1.94"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.405"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2594.bloodjournal8762594"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404283301703"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91150-2"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-551"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910520320"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1997.6.587"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1994.5.3-381"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.1.169"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.1.157"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1995.4.73"},{"issue":"1","key":"e_1_2_6_15_2","article-title":"Autologous EBV\u2010specific cytotoxic T cells to treat EBV\u2010associated posttransplant lymphoproliferative disease","volume":"90","author":"Comoli P","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199705150-00002"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1998.7.257"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1155"}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0463.2002.100205.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0463.2002.100205.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T17:55:06Z","timestamp":1697565306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0463.2002.100205.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1034\/j.1600-0463.2002.100205.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0463.2002.100205.x","archive":["Portico"],"relation":{},"ISSN":["0903-4641","1600-0463"],"issn-type":[{"value":"0903-4641","type":"print"},{"value":"1600-0463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]},"assertion":[{"value":"2002-06-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}